vs
Side-by-side financial comparison of BWX Technologies, Inc. (BWXT) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $860.2M, roughly 1.2× BWX Technologies, Inc.). Hologic runs the higher net margin — 17.1% vs 10.6%, a 6.5% gap on every dollar of revenue. On growth, BWX Technologies, Inc. posted the faster year-over-year revenue change (26.1% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $50.1M). Over the past eight quarters, BWX Technologies, Inc.'s revenue compounded faster (12.4% CAGR vs 1.5%).
BWX Technologies, Inc. is a company headquartered in Lynchburg, Virginia that supplies nuclear components and fuel internationally.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
BWXT vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $860.2M | $1.0B |
| Net Profit | $91.2M | $179.1M |
| Gross Margin | — | 56.0% |
| Operating Margin | 12.4% | 22.6% |
| Net Margin | 10.6% | 17.1% |
| Revenue YoY | 26.1% | 2.5% |
| Net Profit YoY | 20.7% | -10.9% |
| EPS (diluted) | $0.99 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $860.2M | — | ||
| Q4 25 | $885.8M | $1.0B | ||
| Q3 25 | $866.3M | $1.0B | ||
| Q2 25 | $764.0M | $1.0B | ||
| Q1 25 | $682.3M | $1.0B | ||
| Q4 24 | $746.3M | $1.0B | ||
| Q3 24 | $672.0M | $988.0M | ||
| Q2 24 | $681.5M | $1.0B |
| Q1 26 | $91.2M | — | ||
| Q4 25 | $93.0M | $179.1M | ||
| Q3 25 | $82.1M | $187.2M | ||
| Q2 25 | $78.4M | $194.9M | ||
| Q1 25 | $75.5M | $-17.4M | ||
| Q4 24 | $71.0M | $201.0M | ||
| Q3 24 | $69.5M | $178.6M | ||
| Q2 24 | $73.0M | $194.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 56.0% | ||
| Q3 25 | 21.8% | 55.6% | ||
| Q2 25 | 25.1% | 56.3% | ||
| Q1 25 | 24.2% | 37.5% | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | 24.4% | 56.4% | ||
| Q2 24 | 24.7% | 55.4% |
| Q1 26 | 12.4% | — | ||
| Q4 25 | 10.4% | 22.6% | ||
| Q3 25 | 13.1% | 22.6% | ||
| Q2 25 | 13.4% | 24.9% | ||
| Q1 25 | 14.2% | -0.7% | ||
| Q4 24 | 12.4% | 22.5% | ||
| Q3 24 | 14.4% | 23.3% | ||
| Q2 24 | 14.5% | 24.1% |
| Q1 26 | 10.6% | — | ||
| Q4 25 | 10.5% | 17.1% | ||
| Q3 25 | 9.5% | 17.8% | ||
| Q2 25 | 10.3% | 19.0% | ||
| Q1 25 | 11.1% | -1.7% | ||
| Q4 24 | 9.5% | 19.7% | ||
| Q3 24 | 10.3% | 18.1% | ||
| Q2 24 | 10.7% | 19.2% |
| Q1 26 | $0.99 | — | ||
| Q4 25 | $1.02 | $0.79 | ||
| Q3 25 | $0.89 | $0.84 | ||
| Q2 25 | $0.85 | $0.86 | ||
| Q1 25 | $0.82 | $-0.08 | ||
| Q4 24 | $0.77 | $0.87 | ||
| Q3 24 | $0.76 | $0.75 | ||
| Q2 24 | $0.79 | $0.82 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $512.4M | $2.4B |
| Total DebtLower is stronger | $2.0B | $2.5B |
| Stockholders' EquityBook value | $1.3B | $5.2B |
| Total Assets | $4.3B | $9.2B |
| Debt / EquityLower = less leverage | 1.58× | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $512.4M | — | ||
| Q4 25 | $499.8M | $2.4B | ||
| Q3 25 | $79.6M | $2.2B | ||
| Q2 25 | $37.0M | $1.9B | ||
| Q1 25 | $55.4M | $1.6B | ||
| Q4 24 | $74.1M | $2.0B | ||
| Q3 24 | $35.5M | $2.3B | ||
| Q2 24 | $48.3M | $2.4B |
| Q1 26 | $2.0B | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $5.2B | ||
| Q3 25 | $1.2B | $5.0B | ||
| Q2 25 | $1.2B | $4.8B | ||
| Q1 25 | $1.1B | $4.6B | ||
| Q4 24 | $1.1B | $4.8B | ||
| Q3 24 | $1.1B | $5.1B | ||
| Q2 24 | $998.5M | $5.0B |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $9.2B | ||
| Q3 25 | $3.8B | $9.0B | ||
| Q2 25 | $3.7B | $8.8B | ||
| Q1 25 | $3.1B | $8.5B | ||
| Q4 24 | $2.9B | $8.7B | ||
| Q3 24 | $2.9B | $9.2B | ||
| Q2 24 | $2.8B | $8.9B |
| Q1 26 | 1.58× | — | ||
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $92.6M | $229.9M |
| Free Cash FlowOCF − Capex | $50.1M | $215.2M |
| FCF MarginFCF / Revenue | 5.8% | 20.5% |
| Capex IntensityCapex / Revenue | 4.9% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.02× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $328.1M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $92.6M | — | ||
| Q4 25 | $127.0M | $229.9M | ||
| Q3 25 | $143.2M | $355.1M | ||
| Q2 25 | $159.0M | $343.3M | ||
| Q1 25 | $50.6M | $169.4M | ||
| Q4 24 | $276.9M | $189.3M | ||
| Q3 24 | $32.6M | $367.0M | ||
| Q2 24 | $65.9M | $405.8M |
| Q1 26 | $50.1M | — | ||
| Q4 25 | $56.8M | $215.2M | ||
| Q3 25 | $94.9M | $341.4M | ||
| Q2 25 | $126.3M | $330.5M | ||
| Q1 25 | $17.3M | $153.9M | ||
| Q4 24 | $224.4M | $172.5M | ||
| Q3 24 | $-7.7M | $350.6M | ||
| Q2 24 | $35.5M | $385.3M |
| Q1 26 | 5.8% | — | ||
| Q4 25 | 6.4% | 20.5% | ||
| Q3 25 | 11.0% | 32.5% | ||
| Q2 25 | 16.5% | 32.3% | ||
| Q1 25 | 2.5% | 15.3% | ||
| Q4 24 | 30.1% | 16.9% | ||
| Q3 24 | -1.1% | 35.5% | ||
| Q2 24 | 5.2% | 38.1% |
| Q1 26 | 4.9% | — | ||
| Q4 25 | 7.9% | 1.4% | ||
| Q3 25 | 5.6% | 1.3% | ||
| Q2 25 | 4.3% | 1.3% | ||
| Q1 25 | 4.9% | 1.5% | ||
| Q4 24 | 7.0% | 1.6% | ||
| Q3 24 | 6.0% | 1.7% | ||
| Q2 24 | 4.5% | 2.0% |
| Q1 26 | 1.02× | — | ||
| Q4 25 | 1.37× | 1.28× | ||
| Q3 25 | 1.74× | 1.90× | ||
| Q2 25 | 2.03× | 1.76× | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 3.90× | 0.94× | ||
| Q3 24 | 0.47× | 2.05× | ||
| Q2 24 | 0.90× | 2.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BWXT
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
